Adenocarcinoma of the breast metastatic to malignant lymphoma

JAMA ◽  
1966 ◽  
Vol 195 (11) ◽  
pp. 963-965 ◽  
Author(s):  
G. L. Woolam
Keyword(s):  
Malignant Lymphoma

Clinicopathological study of primary malignant lymphoma of the large intestine in Japan

2001 ◽  
Vol 120 (5) ◽  
pp. A257-A257
Author(s):  
K KAMIYA ◽  
H GOTO ◽  
Y NIWA ◽  
N OHMIYA ◽  
T HAYAKAWA
Keyword(s):  
Malignant Lymphoma ◽  
Large Intestine ◽  
Clinicopathological Study

Malignant lymphoma occurring in patient and pet

JAMA ◽  
1966 ◽  
Vol 196 (1) ◽  
pp. 99-101 ◽  
Author(s):  
L. M. Drusin
Keyword(s):  
Malignant Lymphoma

Cases of Malignant Lymphoma which EUS-FNA was Useful for Diagnosis

Endoscopy ◽  
2011 ◽  
Vol 43 (S 03) ◽  
Author(s):  
Morishima Tomomasa
Keyword(s):  
Malignant Lymphoma

Primary Pituitary Malignant Lymphoma Was Difficult to Differentiate from Nonfunctioning Pituitary Adenoma: A Case Report

2016 ◽  
Vol 77 (S 02) ◽  
Author(s):  
Yuta Murakami ◽  
Shinya Jinguji ◽  
Yugo Kishida ◽  
Taku Sato ◽  
Tadashi Watanabe ◽  
...  
Keyword(s):  
Case Report ◽  
Pituitary Adenoma ◽  
Malignant Lymphoma ◽  
Nonfunctioning Pituitary Adenoma

11. International Conference on Malignant Lymphoma: Neue Therapieoptionen bei B- und T-Zell-Lymphomen

2011 ◽  
Vol 02 (04) ◽  
pp. 164-165
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Malignant Lymphoma ◽  
International Conference

Die auf dem 11. ICML-Kongress vorgestellten Studiendaten zeigen für Lenalidomid (Revlimid®)* eine wichtige Rolle bei der Entwicklung neuer Behandlungsoptionen jenseits der Chemotherapie beim diffus großzelligen B-Zell-Lymphom (DLBCL) als auch beim indolenten B-Zell NHL-Lymphom. Als neue Therapieoption bei peripheren T-Zell-Lymphomen (PTCL) werden auch die Histon-Deacetylase (HDAC)-Hemmer wie Romidepsin steigende Bedeutung erhalten, meinte Prof. Bertrand Coiffier, Lyon/Frankreich, von der renommierten GELA-Studiengruppe.

Intrathoracic manifestations in malignant lymphoma

1979 ◽  
Vol 15 (1) ◽  
pp. 141
Author(s):  
BJ Jung ◽  
JY Lee ◽  
SS Kim ◽  
SK Park
Keyword(s):  
Malignant Lymphoma

Statistical analysis of cutaneous malignant lymphoma in the department of dermatology, Akita university hospital.

1989 ◽  
Vol 51 (2) ◽  
pp. 304-309
Author(s):  
Noriko SATO ◽  
Okitaka MAIE ◽  
Toshiko MASAHASHI ◽  
Hironobu MURAI ◽  
Yuhei TADA ◽  
...  
Keyword(s):  
Statistical Analysis ◽  
Malignant Lymphoma ◽  
University Hospital

A Case of Malignant Lymphoma with Subglottic Stenosis

2018 ◽  
Vol 69 (1) ◽  
pp. 17-21
Author(s):  
Aki Fukumoto ◽  
Akira Doi
Keyword(s):  
Malignant Lymphoma ◽  
Subglottic Stenosis

A Case of Malignant Lymphoma that Healed Completely after Oral Administrations of 4-Hydroxybenzaldehyde

2018 ◽  
Vol 1 (1) ◽  
pp. 01-02
Keyword(s):  
Cancer Patient ◽  
Malignant Lymphoma ◽  
Large Dose ◽  
Side Effect ◽  
Small Dose ◽  
Severe Hemorrhage ◽  
Tumor Agent

In 1969, Mutsuyuki Kochi [1, 2] developed 4-Hydroxybenzaldehyde for use as a novel anti-tumor agent without side effect and patent it. Accordingly, this medicine is capable of preventing carcinogenesis when used in sufficient quantity. To treat advanced cancers, an oncologist should start with giving the cancer patient a small dose of 4-Hydroxybenzaldehyde to avoid the possible severe hemorrhage of a tumor caused by excessive necrosis. Therefore, it has useful applications in treating lymphomas and leukemias. Consequently, those who have these diseases can receive a considerably large dose of the medicine.

Sign in / Sign up

Export Citation Format

Share Document